Target intelligence / Profile preview

Deubiquitinase DESI2 (DESI2)

Target
DESI2
Molecular classification
Enzyme, Deubiquitinase, S-depalmitoylase, Peptidase (PPPDE peptidase domain-containing protein)
01

Overview

Deubiquitinase DESI2 is an enzyme involved in the removal of ubiquitin from specific protein substrates, notably exhibiting activity against 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains and mediating deubiquitination of ribosomal protein S7 (RPS7), which leads to its stabilization. DESI2 also possesses S-depalmitoylase activity, meaning it can remove palmitoyl groups from proteins, and is involved in macromolecule depalmitoylation and proteolysis. By regulating protein ubiquitination and palmitoylation status, DESI2 plays an important role in maintaining cellular protein homeostasis and is potentially implicated in disease, including cancer. It is considered a prospective therapeutic target, but as of now, no approved drugs or specific inhibitors are noted in the literature. Notes on aliases and functional annotations: Many aliases derive from previous gene/protein nomenclature standards and protein domains but all refer to the same human protein product. No major sources list established drugs or highly specific biomarkers related to DESI2, and its status as a therapeutic target is emerging rather than established in clinical practice.

Other names
Desumoylating isopeptidase 2PPPDE peptidase domain-containing protein 1Protein FAM152AC1orf121FAM152APPPDE1CGI-146PNAS-4DESI-2S-depalmitoylase DESI2Palmitoyl protein thioesterase DESI2Family with sequence similarity 152, member A
02

Mechanism of action

Inhibition of deubiquitination (hypothetical, no clinically approved inhibitors or specific reference drugs listed); Inhibition or modulation of S-depalmitoylase activity (hypothetical)

03

Biological functions

Protein deubiquitinationProtein depalmitoylationProtein stability regulationProteolysisCellular protein homeostasis
04

Disease associations

CancerOther (evidence for association with anterior segment dysgenesis and microphthalmia, but not centrally established disease mechanisms)
05

Safety considerations

Unknown/off-target effects due to broad substrate specificity possiblePotential for disruption of protein homeostasis if inhibited or activated; specific concerns not documented in clinical or preclinical reports

Beyond the preview

Go deeper on Deubiquitinase DESI2 (DESI2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deubiquitinase DESI2 (DESI2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call